CN101432262B - 作为11-β-羟类固醇脱氢酶1的抑制剂的环己基取代的吡咯烷酮类 - Google Patents
作为11-β-羟类固醇脱氢酶1的抑制剂的环己基取代的吡咯烷酮类 Download PDFInfo
- Publication number
- CN101432262B CN101432262B CN2007800148098A CN200780014809A CN101432262B CN 101432262 B CN101432262 B CN 101432262B CN 2007800148098 A CN2007800148098 A CN 2007800148098A CN 200780014809 A CN200780014809 A CN 200780014809A CN 101432262 B CN101432262 B CN 101432262B
- Authority
- CN
- China
- Prior art keywords
- cyclohexyl
- chloro
- fluoro
- compound
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCc1ccc(*)cc1 Chemical compound CCc1ccc(*)cc1 0.000 description 4
- ABMGMVVQYFPXDH-KRWDZBQOSA-N COC(c(cc1)ccc1-c1cc(Cl)c(C[C@H](CCN2C(CC3)CCC3(F)F)C2=O)c(Cl)c1)=O Chemical compound COC(c(cc1)ccc1-c1cc(Cl)c(C[C@H](CCN2C(CC3)CCC3(F)F)C2=O)c(Cl)c1)=O ABMGMVVQYFPXDH-KRWDZBQOSA-N 0.000 description 1
- ULJIYRFLVPOTMJ-UHFFFAOYSA-N Nc1cc(O)cc(N)c1CN=O Chemical compound Nc1cc(O)cc(N)c1CN=O ULJIYRFLVPOTMJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74544206P | 2006-04-24 | 2006-04-24 | |
| US60/745,442 | 2006-04-24 | ||
| PCT/US2007/067253 WO2007127704A1 (en) | 2006-04-24 | 2007-04-24 | Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101432262A CN101432262A (zh) | 2009-05-13 |
| CN101432262B true CN101432262B (zh) | 2011-06-01 |
Family
ID=38374154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800148098A Expired - Fee Related CN101432262B (zh) | 2006-04-24 | 2007-04-24 | 作为11-β-羟类固醇脱氢酶1的抑制剂的环己基取代的吡咯烷酮类 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7998999B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2049475B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5118692B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101432262B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE543798T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007244971B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0710468A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2649111C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1112398T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2049475T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA016415B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2378574T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008013658A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2049475T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2049475E (cg-RX-API-DMAC7.html) |
| SI (1) | SI2049475T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007127704A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0710273A2 (pt) | 2006-04-21 | 2011-08-09 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, intermediário |
| NZ571175A (en) * | 2006-04-21 | 2011-10-28 | Lilly Co Eli | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| US8088776B2 (en) * | 2006-04-21 | 2012-01-03 | Eli Lilly And Company | Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| CA2649650C (en) | 2006-04-24 | 2014-01-14 | Eli Lilly And Company | Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| ATE472542T1 (de) * | 2006-04-24 | 2010-07-15 | Lilly Co Eli | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer |
| AU2007244863B2 (en) * | 2006-04-25 | 2012-01-19 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| EP2021337B1 (en) | 2006-04-25 | 2010-01-13 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| US7968585B2 (en) | 2006-04-25 | 2011-06-28 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| MX2008013844A (es) * | 2006-04-28 | 2008-11-10 | Lilly Co Eli | Pirrolidinonas substituidas con pieridinilo como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1. |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US8507493B2 (en) | 2009-04-20 | 2013-08-13 | Abbvie Inc. | Amide and amidine derivatives and uses thereof |
| WO2011068927A2 (en) * | 2009-12-04 | 2011-06-09 | Abbott Laboratories | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2018014337A1 (en) * | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| CN108299272B (zh) * | 2018-01-31 | 2019-10-18 | 福州大学 | 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法 |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
| RU2741910C2 (ru) * | 2019-07-09 | 2021-01-29 | Государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации | Соединения, обладающие антиишемическими, антиангинальными, цитопротективными свойствами, способ их получения и их применение, способ лечения нейродегенеративного заболевания, способ лечения психического расстройства |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| EP0705275B1 (en) | 1993-06-21 | 1999-02-03 | Novo Nordisk A/S | Asp-b28 insulin crystals |
| NZ273285A (en) | 1993-09-17 | 1997-10-24 | Novo Nordisk As | Insulin derivatives and compositions thereof |
| US5504188A (en) | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| SE0001899D0 (sv) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| MY141661A (en) * | 2001-09-06 | 2010-05-31 | Schering Corp | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| EP1747198B1 (en) | 2004-05-07 | 2008-06-04 | Janssen Pharmaceutica N.V. | Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| CA2565630C (en) * | 2004-05-07 | 2013-05-28 | Janssen Pharmaceutica N.V. | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| EP1802623A1 (en) | 2004-10-12 | 2007-07-04 | Novo Nordisk A/S | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds |
| WO2006049952A1 (en) * | 2004-10-29 | 2006-05-11 | Eli Lilly And Company | Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| SG161261A1 (en) | 2004-11-10 | 2010-05-27 | Incyte Corp | Lactam compounds and their use as pharmaceuticals |
| ATE399546T1 (de) | 2004-12-20 | 2008-07-15 | Lilly Co Eli | Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1 |
| EP1830840B1 (en) | 2004-12-21 | 2008-07-16 | Eli Lilly And Company | Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| EP1864971A4 (en) | 2005-03-31 | 2010-02-10 | Takeda Pharmaceutical | PROPHYLACTIC / THERAPEUTIC AGENT AGAINST DIABETES |
| US7998959B2 (en) | 2006-01-12 | 2011-08-16 | Incyte Corporation | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| NZ571175A (en) | 2006-04-21 | 2011-10-28 | Lilly Co Eli | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| US8088776B2 (en) | 2006-04-21 | 2012-01-03 | Eli Lilly And Company | Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| BRPI0710273A2 (pt) | 2006-04-21 | 2011-08-09 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, intermediário |
| CA2649650C (en) | 2006-04-24 | 2014-01-14 | Eli Lilly And Company | Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| ATE472542T1 (de) | 2006-04-24 | 2010-07-15 | Lilly Co Eli | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer |
| AU2007244863B2 (en) | 2006-04-25 | 2012-01-19 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| US7968585B2 (en) | 2006-04-25 | 2011-06-28 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| EP2021337B1 (en) | 2006-04-25 | 2010-01-13 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| MX2008013844A (es) | 2006-04-28 | 2008-11-10 | Lilly Co Eli | Pirrolidinonas substituidas con pieridinilo como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1. |
| CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
-
2007
- 2007-04-24 AT AT07761153T patent/ATE543798T1/de active
- 2007-04-24 MX MX2008013658A patent/MX2008013658A/es active IP Right Grant
- 2007-04-24 CA CA2649111A patent/CA2649111C/en not_active Expired - Fee Related
- 2007-04-24 PL PL07761153T patent/PL2049475T3/pl unknown
- 2007-04-24 DK DK07761153.1T patent/DK2049475T3/da active
- 2007-04-24 WO PCT/US2007/067253 patent/WO2007127704A1/en not_active Ceased
- 2007-04-24 EP EP07761153A patent/EP2049475B1/en not_active Not-in-force
- 2007-04-24 ES ES07761153T patent/ES2378574T3/es active Active
- 2007-04-24 BR BRPI0710468-5A patent/BRPI0710468A2/pt not_active IP Right Cessation
- 2007-04-24 US US12/297,877 patent/US7998999B2/en not_active Expired - Fee Related
- 2007-04-24 JP JP2009507921A patent/JP5118692B2/ja not_active Expired - Fee Related
- 2007-04-24 SI SI200730873T patent/SI2049475T1/sl unknown
- 2007-04-24 AU AU2007244971A patent/AU2007244971B2/en not_active Ceased
- 2007-04-24 CN CN2007800148098A patent/CN101432262B/zh not_active Expired - Fee Related
- 2007-04-24 PT PT07761153T patent/PT2049475E/pt unknown
- 2007-04-24 EA EA200870472A patent/EA016415B1/ru not_active IP Right Cessation
-
2012
- 2012-02-24 CY CY20121100194T patent/CY1112398T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007127704A1 (en) | 2007-11-08 |
| BRPI0710468A2 (pt) | 2011-08-16 |
| SI2049475T1 (sl) | 2012-04-30 |
| EP2049475B1 (en) | 2012-02-01 |
| CN101432262A (zh) | 2009-05-13 |
| ES2378574T3 (es) | 2012-04-16 |
| US7998999B2 (en) | 2011-08-16 |
| EA016415B1 (ru) | 2012-04-30 |
| JP5118692B2 (ja) | 2013-01-16 |
| PT2049475E (pt) | 2012-04-12 |
| ATE543798T1 (de) | 2012-02-15 |
| CY1112398T1 (el) | 2015-12-09 |
| CA2649111C (en) | 2013-09-10 |
| AU2007244971B2 (en) | 2012-01-19 |
| DK2049475T3 (da) | 2012-03-05 |
| AU2007244971A1 (en) | 2007-11-08 |
| EP2049475A1 (en) | 2009-04-22 |
| CA2649111A1 (en) | 2007-11-08 |
| PL2049475T3 (pl) | 2012-08-31 |
| MX2008013658A (es) | 2008-11-04 |
| US20090239911A1 (en) | 2009-09-24 |
| JP2009534471A (ja) | 2009-09-24 |
| EA200870472A1 (ru) | 2009-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101448816B (zh) | 作为11-β-羟类固醇脱氢酶1的抑制剂的哌啶基取代的吡咯烷酮类 | |
| CN101432263B (zh) | 作为11-β-羟类固醇脱氢酶1抑制剂的取代的吡咯烷酮类 | |
| CN101432275A (zh) | 11-β-羟类固醇脱氢敏1的抑制剂 | |
| JP5118692B2 (ja) | 11−β−ヒドロキシステロイドデヒドロゲナーゼ1の阻害剤としてのシクロヘキシル置換ピロリジノン | |
| CN101426783A (zh) | 作为11-β-羟基甾族化合物脱氢酶1的抑制剂的环己基吡唑-内酰胺衍生物 | |
| JP5236628B2 (ja) | 11−β−ヒドロキシステロイドデヒドロゲナーゼ1阻害剤としての、シクロヘキシルイミダゾールラクタム誘導体 | |
| CN101432277B (zh) | 11-β-羟甾类脱氢酶1的抑制剂 | |
| EP2021337B1 (en) | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
| CA2648019C (en) | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
| CN1060768C (zh) | 吡唑和吡唑并嘧啶 | |
| CN101541747B (zh) | 作为11-β-羟基甾族化合物脱氢酶1的抑制剂的联苯基酰胺内酰胺衍生物 | |
| EP2035379B1 (en) | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110601 Termination date: 20140424 |